Crecon Medical Assessment Inc.

Crecon Medical Assessment Inc. is a Japanese professional services firm focused on pharmacoeconomics (health economic evaluation) and health technology assessment (HTA). Established on August 1, 2014, the company is headquartered in Shibuya, Tokyo, at the Nagai Memorial Hall of the Pharmaceutical Society of Japan. It operates as part of the Crecon Group, alongside affiliated companies Crecon Research & Consulting Inc. and Crecon Genomics Inc. The firm's core mission is to evaluate the true value of pharmaceuticals and medical devices through advanced modeling, statistical analysis, and simulation techniques, thereby supporting appropriate pricing and healthcare decision-making. The company offers four main service lines: cost-effectiveness analysis, burden of disease analysis, real-world data (RWD) and patient outcome data analysis, and education/consulting. Its cost-effectiveness services include decision model construction, systematic literature reviews, indirect comparisons and network meta-analyses, and budget impact analysis. Burden of disease analysis quantifies the socioeconomic burden of diseases, estimates patient numbers, lifetime medical costs, and expected survival years. The RWD practice covers protocol development, claims data analysis, QOL surveys, conjoint analysis and discrete choice experiments (DCE). Consulting services include internal training and advisory work based on reviews of the UK NICE technology appraisal process. Crecon Medical Assessment positions itself as a specialist partner to the pharmaceutical and medical device industries, helping clients demonstrate value for innovative products in an era of increasing HTA scrutiny. The company is led by President and CEO Hitoshi Kimura, with Director and Chief Operating Officer Shin Kobayashi and Director Bunji Kimura. It recruits analysts with backgrounds in pharmacoeconomics, statistics, epidemiology, or medicine/pharmacy, reflecting the highly technical nature of its work. The firm maintains a strong connection to academic and professional societies, as evidenced by co-hosting career design seminars at the Pharmaceutical Society of Japan's annual meeting and offering HTA expert training programs with the University of Tokyo.

Crecon Medical Assessment Inc. was established on August 1, 2014, in Tokyo, Japan. It was founded as a specialized entity within the Crecon Group to address the growing need for health economic evaluation and health technology assessment (HTA) in the Japanese healthcare market. The company is headquartered in Shibuya, Tokyo, at the Nagai Memorial Hall of the Pharmaceutical Society of Japan, a location that underscores its close ties to the academic and professional pharmacy community. From its inception, the firm focused on providing advanced analytical services to the pharmaceutical and medical device industries. Its early work centered on cost-effectiveness analysis, burden of disease studies, and real-world data analysis, leveraging sophisticated modeling and statistical techniques. Over the years, Crecon Medical Assessment has expanded its service offerings to include education and consulting, particularly around the UK NICE technology appraisal process, reflecting the global convergence of HTA methodologies. The company has been led by President and CEO Hitoshi Kimura, who also holds leadership roles in affiliated Crecon Group companies. Other key executives include Director and COO Shin Kobayashi and Director Bunji Kimura. The firm has actively engaged with the academic community, co-hosting career design seminars at the Pharmaceutical Society of Japan's annual meetings and collaborating with the University of Tokyo on HTA expert training programs. As of 2026, the company continues to operate from its Tokyo headquarters, serving clients in Japan's healthcare sector.

• Company founded in Tokyo, Japan.

• Co-hosted career design seminar at the 146th Annual Meeting of the Pharmaceutical Society of Japan.

• Announced University of Tokyo HTA Expert Training Program.

• Held seminar on basics and practice of cost-effectiveness evaluation (Japanese HTA).

Specialist consultancy providing pharmacoeconomics and HTA analysis to demonstrate the value of pharmaceuticals and medical devices.

• Cost-effectiveness analysis

  Includes decision model construction, systematic literature review, indirect comparison/network meta-analysis, and budget impact analysis.

• Burden of disease analysis

  Quantifies economic burden, estimates patient numbers, lifetime medical costs, and expected survival years.

• Real-world data / patient outcome data analysis

  Includes protocol development, clinical data analysis, claims data analysis, QOL surveys, conjoint analysis/DCE, and exploratory analysis.

• Education and consulting

  Provides seminars, workshops, and consulting based on NICE technology appraisal reviews.

1. 1医療経済評価のクレコンメディカルアセスメント株式会社crecon-ma.co.jp
2. 2会社概要 | 医療経済評価のクレコンメディカルアセスメント株式会社crecon-ma.co.jp
3. 3採用情報 | 医療経済評価のクレコンメディカルアセスメント株式会社crecon-ma.co.jp
4. 4お問い合わせ | 医療経済評価のクレコンメディカルアセスメント株式会社crecon-ma.co.jp
5. 5Wikidata: Crecon Medical Assessment Inc. (Japan)wikidata.org